Distinguished in Leukemia

Agnes Bresler-Guerci

Vandoeuvre-les-nancy, FR 
Distinguished in Leukemia
Vandoeuvre-les-nancy, FR 
OverviewLocationsClinical Research

Overview

Agnes Bresler-Guerci practices in Vandoeuvre-les-nancy, France. Ms. Bresler-Guerci is rated as a Distinguished expert by MediFind in the treatment of Leukemia. Her top areas of expertise are Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Leukemia, and Anemia.

Her clinical research consists of co-authoring 67 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 45 articles and participated in 4 clinical trials in the study of Leukemia.

Gender
Female

Locations

Vandoeuvre-les-nancy, France
Other Locations
Nancy, France
Lyon, France
Nice, France
Rennes, France
Pringy, France
Bordeaux, 33000, France
Caen, 14003, France
Sophie Park, Grenoble, France
Toulouse, France
Nantes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicentre, Open-label Phase II Trial Evaluating the Safety and Efficacy of Ponatinib Induction Followed by Imatinib Maintenance in Adult Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) ≤ 65 Years
A Multicentre, Open-label Phase II Trial Evaluating the Safety and Efficacy of Ponatinib Induction Followed by Imatinib Maintenance in Adult Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) ≤ 65 Years
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib
Study Phase: Phase 2
A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: AG-120
Study Phase: Phase 2
A Phase II Prospective Study GFM-DACORAL-DLI ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
A Phase II Prospective Study GFM-DACORAL-DLI ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
Enrollment Status: Completed
Publish Date: May 14, 2025
Intervention Type: Other, Drug
Study Phase: Phase 2
Phase I/II Study of Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes
Phase I/II Study of Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Drug
Study Drugs: Bortezomib, Cytarabine
Study Phase: Phase 1/Phase 2
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
Enrollment Status: Completed
Publish Date: October 04, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)
A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Drugs: Decitabine, Hydroxyurea
Study Phase: Phase 3
A Phase I/II Study of Eltrombopag in Patients With Chronic Myelomonocytic Leukemia and Thrombocytopenia
A Phase I/II Study of Eltrombopag in Patients With Chronic Myelomonocytic Leukemia and Thrombocytopenia
Enrollment Status: Completed
Publish Date: April 20, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Single-arm Dose Finding Phase Ib Multicenter Study of the Oral Smoothened Antagonist LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
A Single-arm Dose Finding Phase Ib Multicenter Study of the Oral Smoothened Antagonist LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
Enrollment Status: Completed
Publish Date: December 06, 2018
Intervention Type: Drug
Study Phase: Phase 1
Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High)
Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High)
Enrollment Status: Unknown
Publish Date: January 10, 2018
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

67 Total Publications

Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.
Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.
Journal: British journal of haematology
Published: May 02, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bresler-Guerci's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile